Hypersensitivity syndrome associated with zalcitabine therapy [13]

Lancet

Volumn 347, Issue 9006, 1996, Pages 971-

  Tancrede Bohin, E ^a   Grange, F ^a   Bournerias, I ^a   Roujeau, J C ^a   Guillaume, J C ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BROMAZEPAM; COTRIMOXAZOLE; FLUCONAZOLE; FLUOXETINE; ZALCITABINE; ZIDOVUDINE;

ADULT; CASE REPORT; DRUG HYPERSENSITIVITY; EOSINOPHILIA; FEVER; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MALE; PRIORITY JOURNAL; PSEUDOLYMPHOMA; RASH;

EID: 13344277339     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)91459-2     Document Type: Letter

References (5)

1. J-C. Roujeau Rs Stern Severe adverse cutaneous reactions to drugs N Engl J Med 331 1994 1272 1285
2. R. Yarchoan Rv Thomas J-P. Allain Phase I studies of 2`,3`-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT) Lancet i 1988 76 81
3. Mc McNeeley R. Yarchoan S. Broder Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection J Am Acad Dermatol 21 1989 1213 1217
4. Ma Fischl K. Stanley Ac Collier Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease Ann Intern Med 122 1995 24 32
5. J. Lieberman, C. Nauss-Karol, M. Salgo, et al., Safety experience with dideoxycytidine (ddC) in an expanded access population (IX International Conference on AIDS. Berlin: June, 1993 PO-B-3004 (abstr)).